Local view for "http://purl.org/linkedpolitics/eu/plenary/2005-10-26-Speech-3-120"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2005-10-26"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20051026.13.3-120"2
lpv:hasSubsequent	lp_eu:2005-10-26-Speech-3-1212
lpv:speaker	lp:Françoise Grossetête2
lpv:spokenAs	vice-chair; EPP-ED (2004-07-20--2007-02-14)3 substitute; ITRE (2004-07-22--2007-01-14)3 unknown; Union pour un Mouvement Populaire (2004-07-20--2009-07-13)3 member; ENVI (2004-07-21--2007-01-14)3 member; Delegation to the Euro-Mediterranean Parliamentary Assembly (2004-09-15--2009-07-13)3 member; Delegation for relations with the Gulf States, including Yemen (2004-09-15--2007-03-13)3
lpv:translated text	". An emotional and simplistic approach must not be used to tackle the problems linked to human genetics. The European Union cannot allow itself to fall behind its international partners and hold a number of areas for research in abeyance. From the perspective of the great fundamental principles and the universal values that we stand for, it is crucially important entirely to rule out reproductive cloning and the risks of eugenics. Yet, it is just as important to define what is feasible and acceptable to carry out in genetic research, particularly in the context of therapeutic cloning and stem cell research aimed at improving human health. We know that the framework set out for patenting biotechnological inventions is a crucial platform for developing new types of therapy, which, for a large number of ill people, represent an unhoped-for opportunity."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph